{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T17:19:27Z","timestamp":1777051167601,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T00:00:00Z","timestamp":1693958400000},"content-version":"am","delay-in-days":370,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["5R01DA040807"],"award-info":[{"award-number":["5R01DA040807"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.japh.2022.03.015","type":"journal-article","created":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T12:03:49Z","timestamp":1647691429000},"page":"1546-1554","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pharmacy naloxone codispensing: A mixed methods study of practices and perspectives under a statewide standing order program"],"prefix":"10.1016","volume":"62","author":[{"given":"Robin A.","family":"Pollini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susannah","family":"Slocum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2543-561X","authenticated-orcid":false,"given":"Jenny E.","family":"Ozga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3154-8610","authenticated-orcid":false,"given":"Rebecca","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziming","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Traci C.","family":"Green","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander Y.","family":"Walley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.japh.2022.03.015_bib4","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s11606-019-05423-7","article-title":"Association of opioid overdose risk factors and naloxone prescribing in US adults","volume":"35","author":"Lin","year":"2020","journal-title":"J\u00a0Gen Intern Med"},{"issue":"2S","key":"10.1016\/j.japh.2022.03.015_bib5","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1016\/j.japh.2017.01.017","article-title":"Pharmacy-based statewide naloxone distribution: A novel \u201ctop-down, bottom-up\u201d approach","volume":"57","author":"Morton","year":"2017","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"key":"10.1016\/j.japh.2022.03.015_bib7","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.puhe.2019.11.014","article-title":"Coprescription of opioid and naloxone in office-based practice and emergency department settings in the United States","volume":"180","author":"Sohn","year":"2020","journal-title":"Public Health"},{"issue":"6","key":"10.1016\/j.japh.2022.03.015_bib8","doi-asserted-by":"crossref","first-page":"e196215","DOI":"10.1001\/jamanetworkopen.2019.6215","article-title":"Association of naloxone coprescription laws with naloxone prescription dispensing in the United States","volume":"2","author":"Sohn","year":"2019","journal-title":"JAMA Network Open"},{"issue":"6","key":"10.1016\/j.japh.2022.03.015_bib9","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2105\/AJPH.2020.305620","article-title":"Laws mandating Coprescription of naloxone and their impact on naloxone prescription in five US states, 2014\u20132018","volume":"110","author":"Green","year":"2020","journal-title":"Am J Public Health"},{"issue":"6","key":"10.1016\/j.japh.2022.03.015_bib12","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1016\/j.japh.2020.06.008","article-title":"Community pharmacist engagement in opioid use disorder prevention and treatment behaviors: a descriptive analysis","volume":"60","author":"Salwan","year":"2020","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"key":"10.1016\/j.japh.2022.03.015_bib13","author":"Burris"},{"issue":"6","key":"10.1016\/j.japh.2022.03.015_bib14","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.japh.2019.08.009","article-title":"Attitudes and perceptions of naloxone dispensing among a sample of Massachusetts community pharmacy technicians","volume":"59","author":"Kurian","year":"2019","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"issue":"1","key":"10.1016\/j.japh.2022.03.015_bib15","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12954-021-00517-0","article-title":"Pharmacist attitudes and provision of harm reduction services in North Carolina: an exploratory study","volume":"18","author":"Parry","year":"2021","journal-title":"Harm Reduct J"},{"issue":"6","key":"10.1016\/j.japh.2022.03.015_bib16","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.japh.2020.05.016","article-title":"Assessing pharmacy-based naloxone access using an innovative purchase trial methodology","volume":"60","author":"Pollini","year":"2020","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"key":"10.1016\/j.japh.2022.03.015_bib17","series-title":"Executive Office of Health and Human Services. Policy No. 2017-03: Naloxone Dispensing via Standing Order","year":"2017"},{"key":"10.1016\/j.japh.2022.03.015_bib18","unstructured":"The Commonwealth of Massachusetts, Executive Office of Health and Human Services, Department of Public Health, Bureau of Health Professions Licensure. Policy no. 2018-04: naloxone dispensing via standing order. Available at: https:\/\/www.mass.gov\/doc\/policy-2018-04-naloxone-dispensing-via-standing-order\/download#:\u223c:text=Policy%20No.,Naloxone%20Dispensing%20via%20Standing%20Order&text=The%20law%20makes%20important%20strides,for%20this%20life%2Dsaving%20medication. Accessed April 15, 2022."},{"key":"10.1016\/j.japh.2022.03.015_bib19","author":"Ross"},{"issue":"2S","key":"10.1016\/j.japh.2022.03.015_bib20","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.japh.2016.12.077","article-title":"Nonprescription naloxone and syringe sales in the midst of opioid overdose and hepatitis C virus epidemics: Massachusetts, 2015","volume":"57","author":"Stopka","year":"2017","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"issue":"1","key":"10.1016\/j.japh.2022.03.015_bib21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1525822X05282260","article-title":"Using mixed-methods sequential explanatory design: from theory to practice","volume":"18","author":"Ivankova","year":"2006","journal-title":"Field Methods"},{"issue":"1","key":"10.1016\/j.japh.2022.03.015_bib22","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3390\/pharmacy9010030","article-title":"What is known about community pharmacy-based take-home naloxone programs and program interventions? A scoping review","volume":"9","author":"Cid","year":"2021","journal-title":"Pharmacy (Basel)"},{"issue":"2s","key":"10.1016\/j.japh.2022.03.015_bib23","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.japh.2017.01.013","article-title":"Perpetuating stigma or reducing risk? Perspectives from naloxone consumers and pharmacists on pharmacy-based naloxone in 2 states","volume":"57","author":"Green","year":"2017","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"key":"10.1016\/j.japh.2022.03.015_bib24","doi-asserted-by":"crossref","first-page":"103146","DOI":"10.1016\/j.drugpo.2021.103146","article-title":"A\u00a0qualitative study of a publicly funded pharmacy-dispensed naloxone program","volume":"92","author":"Antoniou","year":"2021","journal-title":"Int J Drug Policy"},{"issue":"3","key":"10.1016\/j.japh.2022.03.015_bib25","first-page":"367","article-title":"Beliefs associated with pharmacy-based naloxone: a qualitative study of pharmacy-based naloxone purchasers and people at risk for opioid overdose","volume":"96","author":"Donovan","year":"2019","journal-title":"J\u00a0Urban Health"},{"issue":"1","key":"10.1016\/j.japh.2022.03.015_bib26","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.japh.2021.09.012","article-title":"Implementation of academic detailing for pharmacists on opioid use disorder and harm reduction","volume":"62","author":"DiPaula","year":"2022","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"issue":"6","key":"10.1016\/j.japh.2022.03.015_bib27","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.japh.2021.06.004","article-title":"Community pharmacists in Virginia dispensing naloxone under a standing order: a qualitative study","volume":"61","author":"Ijioma","year":"2021","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"issue":"1","key":"10.1016\/j.japh.2022.03.015_bib28","first-page":"40","article-title":"Challenges and facilitators of implementing a physician-approved naloxone protocol: a mixed-methods study","volume":"15","author":"Hincapie","year":"2021","journal-title":"J\u00a0Addict Med"},{"issue":"5","key":"10.1016\/j.japh.2022.03.015_bib29","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.japh.2020.01.030","article-title":"Evaluation of naloxone access, pricing, and barriers to dispensing in Tennessee retail community pharmacies","volume":"60","author":"Spivey","year":"2020","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"issue":"3","key":"10.1016\/j.japh.2022.03.015_bib30","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.japh.2020.11.023","article-title":"Educational programs implemented for pharmacists after state passage of a standing order for naloxone: a systematic review of current practices","volume":"61","author":"Freibott","year":"2021","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"key":"10.1016\/j.japh.2022.03.015_bib31","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.drugalcdep.2018.03.032","article-title":"Predicting pharmacy naloxone stocking and dispensing following a statewide standing order, Indiana 2016","volume":"188","author":"Meyerson","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.japh.2022.03.015_bib32","doi-asserted-by":"crossref","first-page":"103513","DOI":"10.1016\/j.drugpo.2021.103513","article-title":"Does naloxone provision lead to increased substance use? A systematic review to assess if there is evidence of a \u2018moral hazard\u2019 associated with naloxone supply","volume":"100","author":"Tse","year":"2022","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.japh.2022.03.015_bib33","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.drugpo.2019.09.021","article-title":"Attitudes and availability: a comparison of naloxone dispensing across chain and independent pharmacies in rural and urban areas in Alabama","volume":"74","author":"Sisson","year":"2019","journal-title":"Int J Drug Policy"},{"issue":"31","key":"10.1016\/j.japh.2022.03.015_bib34","doi-asserted-by":"crossref","first-page":"679","DOI":"10.15585\/mmwr.mm6831e1","article-title":"Vital signs: pharmacy-based naloxone dispensing - United States, 2012\u20132018","volume":"68","author":"Guy","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"10","key":"10.1016\/j.japh.2022.03.015_bib35","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1007\/s11606-020-06577-5","article-title":"Individual and community factors associated with naloxone co-prescribing among long-term opioid patients: a retrospective analysis","volume":"36","author":"Stein","year":"2021","journal-title":"J\u00a0Gen Intern Med"},{"issue":"5","key":"10.1016\/j.japh.2022.03.015_bib36","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1001\/jama.2019.7988","article-title":"Naloxone co-prescribing to patients receiving prescription opioids in the medicare part D program, United States, 2016\u20132017","volume":"322","author":"Jones","year":"2019","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.japh.2022.03.015_bib37","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1007\/s11606-015-3394-3","article-title":"Overdose education and naloxone for patients prescribed opioids in primary care: a qualitative study of primary care staff","volume":"30","author":"Binswanger","year":"2015","journal-title":"J\u00a0Gen Intern Med"},{"issue":"2","key":"10.1016\/j.japh.2022.03.015_bib38","first-page":"122","article-title":"Academic detailing pilot for naloxone prescribing among primary care providers in San Francisco","volume":"49","author":"Behar","year":"2017","journal-title":"Fam Med"},{"issue":"6","key":"10.1016\/j.japh.2022.03.015_bib39","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s11606-018-4397-7","article-title":"Increasing naloxone co-prescription for patients on chronic opioids: a student-led initiative","volume":"33","author":"Freise","year":"2018","journal-title":"J\u00a0Gen Intern Med"},{"issue":"2","key":"10.1016\/j.japh.2022.03.015_bib40","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/ajad.13136","article-title":"A\u00a0healthcare system-level intervention to increase naloxone availability for patients with opioid prescriptions","volume":"30","author":"Siff","year":"2021","journal-title":"Am J Addict"},{"issue":"2s","key":"10.1016\/j.japh.2022.03.015_bib41","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1016\/j.japh.2017.01.002","article-title":"Implementing an overdose education and naloxone distribution program in a health system","volume":"57","author":"Devries","year":"2017","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"issue":"12","key":"10.1016\/j.japh.2022.03.015_bib42","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1093\/pm\/pnx243","article-title":"Group visits for overdose education and naloxone distribution in primary care: a pilot quality improvement initiative","volume":"18","author":"Spelman","year":"2017","journal-title":"Pain Med"},{"issue":"5","key":"10.1016\/j.japh.2022.03.015_bib43","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.japh.2020.03.005","article-title":"Revisiting pharmacy-based naloxone with pharmacists and naloxone consumers in 2 states: 2017 perspectives and evolving approaches","volume":"60","author":"Green","year":"2020","journal-title":"J\u00a0Am Pharm Assoc (2003)"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319122000875?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319122000875?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:51:00Z","timestamp":1761544260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319122000875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1544319122000875"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2022.03.015","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacy naloxone codispensing: A mixed methods study of practices and perspectives under a statewide standing order program","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2022.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}